Arovella licences novel monoclonal antibody from MD Anderson
Filed with ASX · · 32 pages · English
• Webinar to be held at 11:00 am AEDT today discussing the licence from MD Anderson. Click here to register. PERTH, AUSTRALIA 13 December 2021: Arovella Therapeutics, (ASX: ALA), a biotechnology company focused on developing its invariant Natural Killer T (iNKT) cell therapy platform, today announces that it has signed a global, exclusive licence agreement with The University of Texas MD Anderson
Arovella Therapeutics Limited on 6ix
In the deck
Earlier from Arovella Therapeutics
- Chile Ministry of Health Approval Granted for ZolpiMist
- GM presentation
- Dr Reuben Benjamin Appointed to SUDA iNKT Cell Therapy SAB
- SUDA signs Licence and Distribution Agreement with STADA
- ZolpiMist Update
Later from Arovella Therapeutics
- AGM FY21 Presentation
- Arovella Completes $4.57M Placement & Launches $1.5M SPP
- SPP Offer Booklet
- Investor Presentation
- Arovella SPP Closed early over subscribed
Follow Arovella Therapeutics into a list and get an email when it puts out news.
Follow Arovella Therapeutics